Published in Mol Clin Oncol on February 25, 2015
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol (2015) 0.85
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol (2010) 16.24
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med (1999) 9.40
Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol (1992) 8.82
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci (2000) 2.52
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst (2000) 2.34
Serum insulin-like growth factor-I and breast cancer. Int J Cancer (2000) 1.82
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer (2002) 1.24
Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab (1997) 1.03
Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer (2007) 1.02
Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev (2007) 1.02
Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov (2012) 1.00
Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab (1994) 0.91
Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol (2008) 0.88
Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology (2004) 0.85
Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril (1991) 0.84
Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol (2013) 0.81